Purple Biotech announced that the USPTO has issued a Notice of Allowance for a patent application covering tri-specific antibody constructs and methods of use. This expands the company's intellectual property portfolio for its CAPTN-3 platform, potentially strengthening its competitive position in the immunotherapy space.
Purple Biotech announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent application related to its tri-specific antibody constructs. This is significant because it expands the company's intellectual property portfolio, specifically supporting its proprietary CAPTN-3 platform for conditionally activated multispecific antibodies. For traders, this is a moderate positive catalyst in the short term, as it de-risks the company's technology and provides a competitive advantage. In the long term, a stronger patent portfolio can attract partnerships and investment, but the ultimate impact depends on the successful development and commercialization of drugs using this platform. The key opportunity is for PPBT to leverage this IP to advance its clinical pipeline.